{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T08:29:23Z","timestamp":1785227363088,"version":"3.55.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Therapeutic antibody-epitope conjugates (AECs) are promising new modalities to deliver immunogenic epitopes and redirect virus-specific T-cell activity to cancer cells. Nevertheless, many aspects of these antibody conjugates require optimization to increase their efficacy. Here we evaluated different strategies to conjugate an EBV epitope (YVL\/A2) preceded by a protease cleavage site to the antibodies cetuximab and trastuzumab. Three approaches were taken: chemical conjugation (i.e. a thiol-maleimide reaction) to reduced cysteine side chains, heavy chain C-terminal enzymatic conjugation using sortase A, and genetic fusions, to the heavy chain (HC) C-terminus. All three conjugates were capable of T-cell activation and target-cell killing <jats:italic>via<\/jats:italic> proteolytic release of the EBV epitope and expression of the antibody target was a requirement for T-cell activation. Moreover, AECs generated with a second immunogenic epitope derived from CMV (NLV\/A2) were able to deliver and redirect CMV specific T-cells, in which the amino sequence of the attached peptide appeared to influence the efficiency of epitope delivery. Therefore, screening of multiple protease cleavage sites and epitopes attached to the antibody is necessary. Taken together, our data demonstrated that multiple AECs could sensitize cancer cells to virus-specific T cells.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1183914","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T05:44:25Z","timestamp":1684215865000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of methods generating antibody-epitope conjugates for targeting cancer with virus-specific T cells"],"prefix":"10.3389","volume":"14","author":[{"given":"Willemijn","family":"van der Wulp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Gram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Bleijlevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate S.","family":"Hagedoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Araman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robbert Q.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Wouter","family":"Drijfhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W. H. I.","family":"Parren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Hibbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob C.","family":"Hoeben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander I.","family":"van Kasteren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Schuurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike E.","family":"Ressing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam H. M.","family":"Heemskerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41591-018-0266-5","article-title":"Low and variable tumor reactivity of the intratumoral tcr repertoire in human cancers","volume":"25","author":"Scheper","year":"2019","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2515135518763280","article-title":"Bispecific antibodies in cancer immunotherapy","volume":"6","author":"Dahlen","year":"2018","journal-title":"Ther Adv Vaccines Immunother"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020287","article-title":"Overcoming challenges for Cd3-bispecific antibody therapy in solid tumors","volume":"13","author":"Middelburg","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-485623","article-title":"Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy","volume":"121","author":"Teachey","year":"2013","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2614","article-title":"Dissection of T-cell antigen specificity in human melanoma","volume":"72","author":"Andersen","year":"2012","journal-title":"Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41467-019-08534-1","article-title":"Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy","volume":"10","author":"Rosato","year":"2019","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.38","article-title":"T Cell responses to cytomegalovirus","volume":"16","author":"Klenerman","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev.immunol.17.1.51","article-title":"Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses","volume":"17","author":"Yewdell","year":"1999","journal-title":"Annu Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1146\/annurev.immunol.25.022106.141553","article-title":"Cellular responses to viral infection in humans: lessons from Epstein-Barr virus","volume":"25","author":"Hislop","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41375-018-0160-7","article-title":"Antibodies conjugated with viral antigens elicit a cytotoxic T cell response against primary cll ex vivo","volume":"33","author":"Schneidt","year":"2019","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-591412","article-title":"Antigen-armed antibodies targeting b lymphoma cells effectively activate antigen-specific Cd4+ T cells","volume":"125","author":"Yu","year":"2015","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0404-8","article-title":"Antibody-mediated delivery of viral epitopes to tumors harnesses cmv-specific T cells for cancer therapy","volume":"38","author":"Millar","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01962","article-title":"Sensitization of tumors for attack by virus-specific Cd8+ T-cells through antibody-mediated delivery of immunogenic T-cell epitopes","volume":"10","author":"Sefrin","year":"2019","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.copbio.2019.11.020","article-title":"Bispecific antibodies in cancer immunotherapy","volume":"65","author":"Rader","year":"2020","journal-title":"Curr Opin Biotechnol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.Mcr-19-0582","article-title":"Antibody-drug conjugates: a comprehensive review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ymeth.2013.07.018","article-title":"A simple, robust and highly efficient transient expression system for producing antibodies","volume":"65","author":"Vink","year":"2014","journal-title":"Methods"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1600-065x.1979.tb00288.x","article-title":"Monoclonal antibodies for analysis of the hla system","volume":"47","author":"Brodsky","year":"1979","journal-title":"Immunol Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-587840","article-title":"Therapeutic targeting of the bcr-associated protein Cd79b in a tcr-based approach is hampered by aberrant expression of Cd79b","volume":"125","author":"Jahn","year":"2015","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.08.010","article-title":"A broad and systematic approach to identify b cell malignancy-targeting tcrs for multi-Antigen-Based T cell therapy","volume":"30","author":"Meeuwsen","year":"2022","journal-title":"Mol Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1201586109","article-title":"Promiscuous binding of extracellular peptides to cell surface class I mhc protein","volume":"109","author":"Eisen","year":"2012","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B25","doi-asserted-by":"publisher","first-page":"207ra144","DOI":"10.1126\/scitranslmed.3006682","article-title":"Tumor-specific activation of an egfr-targeting probody enhances therapeutic index","volume":"5","author":"Desnoyers","year":"2013","journal-title":"Sci Transl Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2016.05.020","article-title":"Counter selection substrate library strategy for developing specific protease substrates and probes","volume":"23","author":"Poreba","year":"2016","journal-title":"Cell Chem Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.233","article-title":"Targeted coating with antigenic peptide renders tumor cells susceptible to Cd8(+) T cell-mediated killing","volume":"21","author":"Kang","year":"2013","journal-title":"Mol Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold tumors: a therapeutic challenge for immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.154","article-title":"Targeting neoantigens to augment antitumour immunity","volume":"17","author":"Yarchoan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cbpa.2019.04.019","article-title":"Tag and release: strategies for the intracellular cleavage of protein conjugates","volume":"52","author":"Baumann","year":"2019","journal-title":"Curr Opin Chem Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/s0960-894x(98)00609-x","article-title":"Cathepsin b-sensitive dipeptide prodrugs. 1. a model study of structural requirements for efficient release of doxorubicin","volume":"8","author":"Dubowchik","year":"1998","journal-title":"Bioorg Med Chem Lett"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic Large cell lymphoma","volume":"30","author":"Senter","year":"2012","journal-title":"Nat Biotechnol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.67.12.7428-7435.1993","article-title":"Hla A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein Lmp2","volume":"67","author":"Lee","year":"1993","journal-title":"J Virol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0343","article-title":"Optimization of a pegylated glucuronide-monomethylauristatin e linker for antibody-drug conjugates","volume":"16","author":"Burke","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3212","article-title":"Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index","volume":"33","author":"Lyon","year":"2015","journal-title":"Nat Biotechnol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/0471140864.ps1503s56","article-title":"Site-specific protein labeling Via sortase-mediated transpeptidation","volume":"3","author":"Popp","year":"2009","journal-title":"Curr Protoc Protein Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)46935-4","article-title":"Is protein turnover thermodynamically controlled","volume":"253","author":"McLendon","year":"1978","journal-title":"J Biol Chem"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119523","article-title":"Protein aggregation and immunogenicity of biotherapeutics","volume":"585","author":"Pham","year":"2020","journal-title":"Int J Pharm"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-014-1541-x","article-title":"Small amounts of Sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics","volume":"32","author":"Ahmadi","year":"2015","journal-title":"Pharm Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2020.08.019","article-title":"Antibody stability: a key to performance - analysis, influences and improvement","volume":"177","author":"Ma","year":"2020","journal-title":"Biochimie"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat Biotechnol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2116738119","article-title":"Harnessing anti-cytomegalovirus immunity for local immunotherapy against solid tumors","volume":"119","author":"Cuburu","year":"2022","journal-title":"PNAS"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0121","article-title":"Silencing fc domains in T cell-engaging bispecific antibodies improves T-cell trafficking and antitumor potency","volume":"7","author":"Wang","year":"2019","journal-title":"Cancer Immunol Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1183914\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T05:44:33Z","timestamp":1684215873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1183914\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,16]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2023.1183914"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1183914","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,16]]},"article-number":"1183914"}}